You are here

News

March 18, 2010
Update on RV144

The Thai Phase III HIV vaccine clinical trial, also known as RV144, was the largest HIV vaccine study ever conducted and involved more than 16,000 volunteers in Thailand. This U.S. Army-sponsored HIV vaccine study showed that an investigational HIV vaccine regimen was safe and modestly effective (31.2% efficacy, mITT analysis) at reducing the rate of HIV infection compared to placebo.

...

February 24, 2010
Ambassador Goosby Site Visit

Ambassador Goosby visited MHRP’s implementing partner, the Nigeria Ministry of Defense (NMOD) Emergency Plan Implementing committee (EPIC), on February 24, 2010. During his visit, Ambassador Goosby participated in a meeting with COL Ayemoba (representing the chairman of the EPIC from NMOD, Brig. Gen. Tor Umar). The ambassador commended the DOD-NMOD achievements to date, highlighting especially...

February 24, 2010
Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya

A new study published in AIDS Care looked at 222 HIV-positive adult tea plantation workers in western Kenya to assess wellbeing over their first two years on ART. Results showed substantial improvements in physical wellbeing during two years after ART initiation. 

Improvements were largest in the first few months after initiating treatment but were generally sustained over two years....

February 18, 2010
RV144 Update at CROI

COL Nelson Michael, MHRP Director, made a presentation today at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) in San Francisco, California. COL Michael showed some new data on risk factors and breakthrough infections. He also shared some ideas on the way forward for HIV vaccine development. 

MHRP has formed four scientific working groups to help guide...

January 28, 2010
Paper published on Phase I/II Study of a Vaccine Candidate in East Africa

RV 172: A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Boosted by a Multiclade HIV-1 Recombinant ADENOVIRUS-5 Vector Vaccine, VRC-HIVADV014-00-VP in HIV Uninfected Adu

1/28/2010

Results from the RV172 study of a vaccine candidate in East Africa conducted by MHRP were published recently in the Journal...

January 15, 2010
RV144 Vaccine Regimen Tops Best of Lists in 2009

The RV144 vaccine regimen used in the Phase III HIV vaccine clinical trial in Thailand was rated number two on TIME magazine’s Top 10 Medical Breakthroughs list for 2009 and number eight on their 50 Best Inventions of the Year.

The vaccine also made Scientific American’s top 10 science stories, Discover magazine’s top 100 science stories (ranked number 13) and Infectious Disease News’...

December 14, 2009
New Insight into Selective Binding Properties of Infectious HIV

Free infectious HIV-1 is widely thought to be the major form of the virus in the blood of infected persons. U.S. Military HIV Research Program (MHRP) researchers, however, have demonstrated that essentially all of the infectious virus particles can bind to the surface of red blood cells isolated from each of 30 normal (non-infected) human donors. The results were published on today in PLoS ONE...

December 11, 2009
Phase Ib Ebola/Marburg Vaccine Clinical Trial Begins

MHRP began a collaborative Phase Ib study to evaluate the safety and immunogenicity of Ebola and Marburg DNA plasmid vaccines in healthy adults in Kampala, Uganda.

This study, called RV247, is a randomized, double-blinded, placebo-controlled study that will evaluate the safety, tolerability, and immunogenicity of two recombinant DNA vaccines: one against Ebola virus and one against...

December 10, 2009
U.S. Ambassador to Tanzania Visits MHRP site in Mbeya

The U.S. Ambassador to the United Republic of Tanzania, Alfonso E. Lenhardt, visited MHRP in Mbeya, TZ November 22-24, 2009. The Ambassador toured the state-of-the-art laboratories, gaining appreciation for the work MHRP carries out in partnership with the civilian hospitals, NGOs, and the Mbalizi Tanzania People’s Defense Forces Hospital.

The Ambassador also met with representatives...

December 8, 2009
World AIDS Day Events

Scientific Collaboration at WRAIR

Walter Reed Army Institute of Research (WRAIR) and MHRP hosted an event to highlight recent achievements in HIV research and share program successes from the PEPFAR program in Kenya. Dr. Merlin Robb, MHRP clinical deputy director, provided a Phase III HIV vaccine trial update, before turning the stage over to Keynote Speaker Dr. David Margolis,...

Pages